EU Approves Janssen Blood Cancer Drug

27.05.2016 - Janssen-Cilag, a subsidiary of US healthcare giant Johnson & Johnson, has been granted conditional approval in Europe for Darzalex (daratumumab) to treat patients with relapsed and...